Skip to main content
Clinical Trials/NCT06980571
NCT06980571CompletedNot Applicable

Randomised Prospective Study of CUSA Versus Radiofrequency Ablation Technique in Liver Resections

Barts & The London NHS Trust1 site in 1 country100 target enrollmentStarted: June 1, 2006Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
100
Locations
1
Primary Endpoint
Blood loss per cm squared of liver parenchyma cut through

Study Overview

Brief Summary

The purpose of this study is to determine whether a particular method of operating on the liver is superior to the "gold" standard commonest technique. CUSA (ultrasonic agitation) will be compared to the newer heat coagulation technique (radiofrequency ablation) and comparisons of blood loss, transfusion requirements, complication rates, hospital stay, effect on liver function, health economics and death rate will be made. The groups will be assessed for comparability in terms of underlying disease, resection type, underlying concurrent illnesses, sex, age, background liver disease. Standardisations of the rest of the operation will be carried out including anaesthetic technique and fluid requirements will be assessed by oesophageal Doppler. 100 patients will be recruited.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 85 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •any adult patient listed for liver resection giving informed consent

Exclusion Criteria

  • •children, non-consent and diminished responsibility

Arms & Interventions

Radiofrequency ablation

Active Comparator

50 patients randomised to radiofrequency ablation technique of liver resection

Intervention: radiofrequency ablation (Device)

CUSA

No Intervention

50 patients having liver resection randomised to CUSA

Outcomes

Primary Outcomes

Blood loss per cm squared of liver parenchyma cut through

Time Frame: operation date until three months from discharge

Secondary Outcomes

  • mortality(inpatient and thirty day mortality)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials